Full-Time

Clinical Account Manager

Multiple Teams

Posted on 9/16/2025

Cleerly

Cleerly

201-500 employees

AI-driven cardiovascular imaging analytics platform

Compensation Overview

$105k - $130k/yr

+ Variable Compensation up to $90,000

Dallas, TX, USA

Hybrid

Field-based role covering TX, OK, AR, MS, LA, IL, IN, MI, and WI with travel 50-80% of the time.

Category
Sales & Account Management
Required Skills
Data Analysis
Requirements
  • You have a degree from an accredited college or university.
  • You bring 5+ years of cardiovascular-related experience, ideally in one of the following: Cardiovascular device or SaaS sales, Hospital-based clinical support (PA, NP, DNP, or RN), Cardiovascular pharmaceuticals or radiopharmaceuticals.
  • You are highly coachable, quick to learn complex medical concepts, and capable of communicating clinical value clearly.
  • You are relationship-driven and thrive in provider-facing environments.
  • You possess exceptional communication, presentation, and stakeholder management skills.
  • You are a self-starter with a high sense of urgency, accountability, and ethical integrity.
  • You’re experienced in navigating complex hospital environments and can tailor your strategy to a variety of stakeholders.
  • You’re agile in dynamic environments and energized by the opportunity to introduce innovative technology into the clinical workflow.
Responsibilities
  • Serve as the primary point of contact for clinical accounts, ensuring successful implementation and sustained adoption of Cleerly’s cardiovascular technology.
  • Deliver ongoing education and training to cardiologists, radiologists, and referring providers on Cleerly’s clinical value and product capabilities.
  • Develop and expand key account relationships with physicians, administrators, and other strategic stakeholders.
  • Identify growth opportunities within existing accounts through data analysis, provider feedback, and referral trends.
  • Partner cross-functionally with sales, implementation, and customer success to ensure seamless support for healthcare partners.
  • Support new product introductions and drive clinician awareness through peer education, onboarding, and in-service training.
  • Maintain accurate records and activity tracking in Salesforce.com.
  • Travel 50–80% within the assigned multi-state territory.

Cleerly Health provides an AI-powered digital platform for cardiovascular care. It analyzes coronary CT angiography (CCTA) heart scans to identify and measure atherosclerosis, including different plaque types, helping clinicians assess heart attack risk more accurately. The platform converts complex imaging data into actionable insights, enabling personalized treatment plans for patients and improved clinical and financial outcomes for healthcare providers. Unlike traditional methods that rely on general risk factors, Cleerly focuses on precise plaque characterization and integrates imaging analysis with care management tools. The company’s goal is to help clinicians diagnose and treat heart disease more precisely, improving patient health while delivering better outcomes for providers.

Company Size

201-500

Company Stage

Series C

Total Funding

$417.8M

Headquarters

New York City, New York

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Value-based care partnerships with Cardiac Care Alliance expand adoption across Texas cardiology practices.
  • Bunkerhill Health collaboration extends FDA-cleared solutions to early detection and imaging evaluation markets.
  • $106M Series C funding from Insight Partners and Battery Ventures accelerates platform scaling.

What critics are saying

  • HeartFlow's established FFRct platform dominates CCTA market with superior payer contracts and provider adoption.
  • FDA intensifies AI imaging scrutiny post-2025 recalls, risking audits of plaque quantification claims.
  • Slow Texas-only Cardiac Care Alliance rollout threatens 3x revenue growth targets post-funding.

What makes Cleerly unique

  • AI-QCT achieves 94.4% agreement with invasive IVUS for plaque quantification across coronary segments.
  • PREVIEW workflow maps stenosis severity to reimbursement thresholds, streamlining prior authorization processes.
  • CONFIRM2 Registry data from 10,750+ patients supports risk stratification and cardiovascular outcomes prediction.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, and vision plans

Stock Options

401(k) matching program

Company wide holidays

Self-managed PTO

Company News

Business Wire
Mar 25th, 2026
Cleerly debuts PREVIEW workflow tool and presents AI-QCT research at ACC.26

Cleerly, a cardiovascular imaging analysis company, will debut Cleerly PREVIEW at the American College of Cardiology's 75th Annual Scientific Session (ACC.26) in New Orleans from 28–30 March 2026. Cleerly PREVIEW is a workflow-support enhancement to the company's AI-enabled quantitative computed tomography platform. It helps clinicians prioritise cases based on coronary artery disease severity whilst streamlining administrative processes like prior authorisation by mapping stenosis ranges to established reimbursement thresholds. The company will also present findings from four scientific abstracts covering plaque quantification, risk stratification and cardiovascular outcomes, including two studies using data from the CONFIRM2 Registry, which currently has over 10,750 participants enrolled. Founded by CEO James K. Min, Cleerly uses FDA-cleared AI-driven solutions for coronary artery disease phenotyping from CT imaging.

Cleerly
Mar 25th, 2026
Cleerly to debut Cleerly PREVIEW and showcase new AI-QCT research at ACC.26.

Cleerly to debut Cleerly PREVIEW and showcase new AI-QCT research at ACC.26. New Product Enhancement and Four Scientific Presentations to Highlight Cleerly's Presence at the 75th Annual Scientific Session & Expo of the American College of Cardiology March 25, 2026 (DENVER, CO) - Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26). The conference will take place March 28-30, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. ACC.26 convenes clinicians, researchers, and innovators from around the world to advance the science and practice of heart care. Cleerly will mark the conference with the launch of Cleerly(R) PREVIEW(TM), a new workflow-support enhancement designed to assist clinicians with case prioritization and streamline administrative processes, such as prior authorization, for coronary artery disease (CAD) imaging. In addition, Cleerly will present findings from four scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including two studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular clinical outcomes. Introducing Cleerly PREVIEW Cleerly PREVIEW is a new workflow-support enhancement to Cleerly's artificial intelligence-enabled quantitative computed tomography (AI-QCT) platform that helps clinicians prioritize cases based on potential severity of coronary artery disease while also facilitating administrative processes like the prior authorization and reimbursement pathway. Key upgrades include greatest diameter stenosis values and stenosis location information, with stenosis ranges mapped to established reimbursement thresholds. "Cleerly PREVIEW was built to bring key stenosis data front and center. By connecting this upfront information directly to reimbursement thresholds, we're helping streamline the administrative workflow and drive efficiency in the prior authorization process," said James K. Min, founder and CEO of Cleerly. Conference Schedule * Saturday, March 28 * Sex-Based Differences in PREVENT Risk, Coronary Calcium, and Noncalcified Plaque by AI Quantitative Coronary CT (1:18-1:25 PM CST). Session 1036: Subclinical Atherosclerosis in Clinical Practice. Moderated Poster Theater 05, Hall E. * Meet Cleerly Leadership (3:00-4:00 PM CST). A meet-and-greet at Cleerly's Booth #1645, offering attendees the opportunity to connect with Cleerly's executive team. See details below. * Sunday, March 29 * AI-Guided Quantitative Coronary CT for Risk Stratification of Major Adverse Cardiovascular Events in Patients with and without Diabetes: CONFIRM 2 Registry (9:42-9:49 AM CST). Session 1082: Intelligence in Action: AI Across the Cardiac Spectrum. Moderated Poster Theater 03, Hall E. * Advanced Imaging to Understand the Relation between Coronary Microvascular Dysfunction and Coronary Plaque Burden and Vascular Remodeling (12:30-1:30 PM CST). Session 1473: Multimodal Imaging 08. Posters, Hall E. Poster #1473-087. * Monday, March 30 * Percent Atheroma Volume by CCTA with AI-QCT Identifies Thresholds for Prognostic Benefit of Revascularization: Insights from the CONFIRM 2 Registry (9:30-10:30 AM CST). Session 1545: Multimodal Imaging 11. Posters, Hall E. Poster #1545-084. Meet Cleerly Leadership Join Cleerly on Saturday, March 28, from 3:00-4:00 PM CST at Booth #1645 for a reception with food and beverages, and the opportunity to connect directly with Cleerly's leadership team. Stop by Booth #1645 throughout the conference for live demonstrations of Cleerly's technology, clinical evidence, and discussions with its expert team. A barista will be on-site Saturday and Sunday throughout exhibit hall hours. To view the full schedule of Cleerly presentations or to schedule a meeting with Cleerly leadership, go to this link. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com. Cleerly Media Contact Christy Sievert [email protected]

HealthTech HotSpot
Mar 20th, 2026
Cleerly AI-QCT Demonstrates high agreement with Invasive IVUS in INVICTUS Registry.

Cleerly AI-QCT Demonstrates high agreement with Invasive IVUS in INVICTUS Registry. Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification DENVER-(BUSINESS WIRE)-#AI - Cleerly, a leader in AI-based cardiovascular imaging analysis, presented findings from its multicenter INVICTUS registry at the recent European Congress of Radiology (ECR 2026) in Vienna, Austria. The presentation titled, "Artificial Intelligence-Based CCTA Quantification of Atherosclerosis Burden: Comparison With IVUS in the INVICTUS Registry" was presented by Rine Nakanishi, MD, PhD, during the Clinical Trials in Radiology: Spotlight Session on March 5, 2026. The analysis has also been simultaneously published in European Radiology. INVICTUS, a multicenter registry of two cohorts of patients prospectively and retrospectively enrolled across 17 centers in Japan, aimed to evaluate the quantification and characterization of atherosclerosis by artificial intelligence-enabled quantitative computed tomography (AI-QCT) against "gold-standard" invasive imaging techniques such as intravascular ultrasound (IVUS), near-infrared spectroscopy IVUS (NIRS-IVUS), and optical coherence tomography (OCT). IVUS is widely used during invasive coronary procedures to assess plaque burden and guide intervention. The authors investigated the diagnostic utility of AI-QCT quantification of coronary atherosclerosis across the whole spectrum of atheroma burden, including diseased and non-diseased continuous vascular segments. Key Findings AI-QCT demonstrated strong correlations compared to invasive "gold-standard" imaging IVUS, showing no significant difference in measuring arterial plaque across the whole coronary segment. AI-QCT showed strong correlation with IVUS (mean difference −0.09%), with 94.4% of measurements falling within the limits of agreement. Strong associations were seen between AI-QCT and IVUS in quantifying external elastic membrane volume (EEM) (r=0.899), lumen volume (r=0.943), plaque volume (r=0.833), length-normalized PAV (r=0.851), and calcium index (r=0.960). AI-QCT also demonstrated 99.1% agreement in classifying the predominant plaque type at the minimum lumen area. Strong correlations were also seen in segments with non-calcified plaque (NCP) and low-attenuation (LAP) for vessel, lumen, and plaque volumes. Clinical and Strategic Implications Unlike physiology-based imaging approaches that focus primarily on ischemia assessment, AI-QCT provides a comprehensive analysis of both total plaque burden and plaque composition using standard coronary computed tomography angiography (CCTA). These findings support the use of noninvasive plaque quantification with standard CCTA for comprehensive coronary plaque assessment. "Every time we reach a scientific milestone that makes accurate plaque characterization more accessible and less invasive, we get closer to our goal of eliminating heart attacks. IVUS has long been the gold standard in invasive plaque imaging, and the findings from INVICTUS represent an important advance in establishing the clinical validity of noninvasive plaque quantification. The strong correlations across multiple metrics support AI-QCT as a reliable tool for comprehensive coronary plaque assessment," said James K. Min, founder and CEO of Cleerly. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com. March 21st, 2026 March 20th, 2026 March 19th, 2026

HIT Consultant
May 6th, 2025
Ai Meets Value-Based Care: Cleerly And Cardiac Care Alliance Join Forces

AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces. by Jasmine Pennic 05/06/2025 Leave a Comment. What You Should Know: – Cleerly, a leader in cardiovascular imaging, and Cardiac Care Alliance, a prominent figure in value-based cardiovascular care solutions, today announced a strategic partnership aimed at significantly enhancing cardiovascular care delivery. – The collaboration will see the integration of Cleerly’s advanced AI-powered coronary artery assessment technology into Cardiac Care Alliance’s extensive cardiovascular care network. The initiative is set to launch initially with cardiology practices in Texas, with ambitions for broader implementation.Optimizing Cardiac Pathways with Advanced AI TechnologyA key objective of this partnership is to refine the diagnostic journey for patients with cardiovascular symptoms. Cardiac Care Alliance will incorporate Cleerly’s Artificial Intelligence–Quantitative Coronary Tomography (AI-QCT) technology into its offerings for payers and practices. The goal is to ensure that symptomatic patients, when appropriate, undergo Cleerly’s noninvasive assessment prior to considering cardiac catheterization procedures

Cleerly
May 6th, 2025
AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection

This collaboration will integrate Cleerly's advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance's cardiovascular care network.

INACTIVE